亨迪药业：盐酸埃克替尼化学原料药上市申请获批准

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of hydrochloride erlotinib, a targeted drug for treating non-small cell lung cancer [1] Group 1: Product Approval - The approval pertains to hydrochloride erlotinib, classified as an EGFR tyrosine kinase inhibitor [1] - This drug is primarily used for treating locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene [1] - It can also be used for patients with advanced non-small cell lung cancer who have failed previous chemotherapy [1]